
The authors present the results of a survey of small- and large-molecule pharmaceutical and biopharmaceutical companies on implementation of Analytical quality by design concepts.
Patrick Johnson is an analytical chemist in analytical sciences/chemical development at GlaxoSmithKline in the UK.

The authors present the results of a survey of small- and large-molecule pharmaceutical and biopharmaceutical companies on implementation of Analytical quality by design concepts.

The authors describe a novel approach for assessing method robustness. This article contains online-bonus material and was copublished with Pharmaceutical Technology Europe.

Published: April 2nd 2010 | Updated:

Published: April 2nd 2017 | Updated: